{"entity":{"id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","aka":[],"tldr":"A phase 1/2 trial of Repotrectinib in advanced solid tumours, run by Turning Point Therapeutics, Inc., now recruiting.","summary":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements is a phase 1/2 interventional study registered as NCT03093116 by Turning Point Therapeutics, Inc., with 500 participants planned, started 2017-03-07 and due to reach its primary completion in 2028-02-29. Interventions recorded: Oral repotrectinib (TPX-0005).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03093116","url":"https://clinicaltrials.gov/study/NCT03093116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["repotrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03093116","phase":"1/2","setting":"A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)","sponsor":"Turning Point Therapeutics, Inc.","enrolled":500,"outcomes":[]},"route":"/trials/nct03093116/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"}]}}